Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4633158 | 0.84 | LMNA (0.55) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2KMT2A | |
| SCHEMBL4632986 | 0.82 | ALDH1A1 (0.60) | HPGDALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL19207465 | 0.79 | SMN1; SMN2 (0.58) | HPGDALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL31145858 | 0.78 | KDM4C (0.47) | ALDH1A1KMT2ATSHR | |
| SCHEMBL31145863 | 0.78 | KDM4C (0.47) | ALDH1A1KMT2ATSHR | |
| SCHEMBL28017511 | 0.76 | MMP13 (0.56) | MMP13HPGDALDH1A1GLACYP1A2 | |
| SCHEMBL21753196 | 0.76 | HPGD (0.79) | MMP13HPGDALDH1A1GLACYP1A2 | |
| SCHEMBL20029114 | 0.76 | ACR (0.43) | MMP13HPGDALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL3144624 | 0.76 | CNR1 (0.41) | SMN1; SMN2KMT2AGAAHDAC6 | |
| SCHEMBL27363106 | 0.76 | HDAC6 (0.35) | MMP13SMN1; SMN2KMT2AHDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004043951-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | CAREX S.A. (FR) | 2004-05-27 | — | — | WO | claimed |
| US-20090156582-A1 | Pyrazole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1622876-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1494673-A4 | COMPOUNDS HAVING UNIQUE CB1 RECEPTOR BINDING SELECTIVITY AND METHODS FOR THEIR PRODUCTION AND USE | RES TRIANGLE INST (US) | 2006-01-18 | — | — | EP | disclosed |
| EP-1494673-A1 | COMPOUNDS HAVING UNIQUE CB1 RECEPTOR BINDING SELECTIVITY AND METHODS FOR THEIR PRODUCTION AND USE | RESEARCH TRIANGLE INSTITUTE (US) | 2005-01-12 | — | — | EP | disclosed |
| WO-2004099157-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| WO-2003088968-A1 | COMPOUNDS HAVING UNIQUE CB1 RECEPTOR BINDING SELECTIVITY AND METHODS FOR THEIR PRODUCTION AND USE | RESEARCH TRIANGLE INSTITUTE (US) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | GSK3B, GSK3A, GSKIP | MMP13 1609/4885HPGD 2563/4885ALDH1A1 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.